Previous studies have demonstrated that ICIs combined with angiogenesis inhibitors was effective.34-37 Data from the phase I trial have shown that anti-CTLA-4 ipilimumab combined with bevacizumab was effective in metastatic melanoma, with an ORR of 19.6%.34 Other clinical trials also displayed favorable ORR of ICIs plus angiogenesis inhibitors in renal and urothelial carcinoma patients.35,38,39 Considering the low ORR of ICIs monotherapy, bevacizumab might be a relatively safe combining choice. This evidence concerns the gene CTLA4 and metastatic melanoma.